CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond

Literature Cited

1. 1.

   Motzer RJ, Tannir NM, McDermott DF, et al. 2018.. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. . N. Engl. J. Med. 378::1277–90
   [Google Scholar]
2. 2.

   Motzer R, Alekseev B, Rha S-Y, et al. 2021.. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. . N. Engl. J. Med. 384::1289–300
   [Google Scholar]
3. 3.

   Rini BI, Plimack ER, Stus V, et al. 2019.. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. . N. Engl. J. Med. 380::1116–27
   [Google Scholar]
4. 4.

   Choueiri TK, Powles T, Burotto M, et al. 2021.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. . N. Engl. J. Med. 384::829–41
   [Google Scholar]
5. 5.

   Choueiri TK, Tomczak P, Park SH, et al. 2021.. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. . N. Engl. J. Med. 385::683–94
   [Google Scholar]
6. 6.

   Laetsch TW, Maude SL, Rives S, et al. 2023.. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. . J. Clin. Oncol. 41::1664–69
   [Google Scholar]
7. 7.

   Lens SM, Tesselaar K, van Oers MH, van Lier RA. 1998.. Control of lymphocyte function through CD27-CD70 interactions. . Semin. Immunol. 10::491–99
   [Google Scholar]
8. 8.

   Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. 2009.. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. . Immunol. Rev. 229::216–31
   [Google Scholar]
9. 9.

   Denoeud J, Moser M. 2011.. Role of CD27/CD70 pathway of activation in immunity and tolerance. . J. Leukoc. Biol. 89::195–203
   [Google Scholar]
10. 10.

    Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. 2022.. The CD70-CD27 axis in oncology: the new kids on the block. . J. Exp. Clin. Cancer Res. 41::12
    [Google Scholar]
11. 11.

    Junker K, Hindermann W, von Eggeling F, et al. 2005.. CD70: a new tumor specific biomarker for renal cell carcinoma. . J. Urol. 173::2150–53
    [Google Scholar]
12. 12.

    Diegmann J, Junker K, Gerstmayer B, et al. 2005.. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. . Eur. J. Cancer 41::1794–801
    [Google Scholar]
13. 13.

    Jilaveanu LB, Sznol J, Aziz SA, et al. 2012.. CD70 expression patterns in renal cell carcinoma. . Hum. Pathol. 43::1394–99
    [Google Scholar]
14. 14.

    Diegmann J, Junker K, Loncarevic IF, et al. 2006.. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. . Neoplasia 8::933–38
    [Google Scholar]
15. 15.

    Wang QJ, Hanada K, Robbins PF, et al. 2012.. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. . Cancer Res. 72::6119–29
    [Google Scholar]
16. 16.

    Ye H, Huang RR, Shuch BM, et al. 2022.. CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma. . J. Clin. Oncol. 40:(Suppl. 6):384
    [Google Scholar]
17. 17.

    Benhamouda N, Sam I, Epaillard N, et al. 2022.. Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma. . Clin. Cancer Res. 28::4983–94
    [Google Scholar]
18. 18.

    Zhang C, Liu J, Zhong JF, Zhang X. 2017.. Engineering CAR-T cells. . Biomark. Res. 5::22
    [Google Scholar]
19. 19.

    Wang M, Munoz J, Goy A, et al. 2020.. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. . N. Engl. J. Med. 382::1331–42
    [Google Scholar]
20. 20.

    Martin T, Usmani SZ, Berdeja JG, et al. 2023.. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. . J. Clin. Oncol. 41::1265–74
    [Google Scholar]
21. 21.

    Panowski SH, Srinivasan S, Tan N, et al. 2022.. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma. . Cancer Res. 82::2610–24
    [Google Scholar]
22. 22.

    Pal S, Tran B, Haanen J, et al. 2022.. 558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: results from the phase 1 COBALT-RCC study. . J. Immunother. Cancer 10:(Suppl. 2):A584
    [Google Scholar]
23. 23.

    Srour S, Kotecha R, Curti B, et al. 2023.. Abstract CT011: a phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC). . Cancer Res. 83:(Suppl. 8):CT011
    [Google Scholar]
24. 24.

    Sun JC, Beilke JN, Lanier LL. 2009.. Adaptive immune features of natural killer cells. . Nature 457::557–61
    [Google Scholar]
25. 25.

    Klingemann H. 2014.. Are natural killer cells superior CAR drivers?. Oncoimmunology 3::e28147
    [Google Scholar]
26. 26.

    Valeri A, Garcia-Ortiz A, Castellano E, et al. 2022.. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. . Front. Immunol. 13::953849
    [Google Scholar]
27. 27.

    Choi E, Chang J-W, Krueger J, et al. 2021.. Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies. . Blood 138:(Suppl. 1):1691
    [Google Scholar]
28. 28.

    McEarchern JA, Oflazoglu E, Francisco L, et al. 2006.. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. . Blood 109::1185–92
    [Google Scholar]
29. 29.

    Aftimos P, Rolfo C, Rottey S, et al. 2017.. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies. . Clin. Cancer Res. 23::6411–20
    [Google Scholar]
30. 30.

    Adam PJ, Terrett JA, Steers G, et al. 2006.. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. . Br. J. Cancer 95::298–306
    [Google Scholar]
31. 31.

    Massard C, Soria J-C, Krauss J, et al. 2019.. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. . Cancer Chemother. Pharmacol. 83::1057–63
    [Google Scholar]
32. 32.

    Sandall S, Anderson M, Jonas M, et al. 2014.. Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). . Cancer Res. 74:(Suppl. 19):2647
    [Google Scholar]
33. 33.

    Pal SK, Forero-Torres A, Thompson JA, et al. 2019.. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. . Cancer 125::1124–32
    [Google Scholar]
34. 34.

    Tannir NM, Forero-Torres A, Ramchandren R, et al. 2014.. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. . Investig. New Drugs 32::1246–57
    [Google Scholar]
35. 35.

    Owonikoko TK, Hussain A, Stadler WM, et al. 2016.. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. . Cancer Chemother. Pharmacol. 77::155–62
    [Google Scholar]
36. 36.

    Wang L, Liu H, Shang X, et al. 2022.. Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma. . Cancer Res. 82:(Suppl. 12):1759
    [Google Scholar]
37. 37.

    Hagemann UB, Mihaylova D, Uran SR, et al. 2017.. Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma. . Oncotarget 8::56311–26
    [Google Scholar]
38. 38.

    Trac N, Oh HS, Jones LI, et al. 2022.. CD70-targeted micelles enhance HIF2α siRNA delivery and inhibit oncogenic functions in patient-derived clear cell renal carcinoma cells. . Molecules 27::8457
    [Google Scholar]
39. 39.

    Chen P, Nogusa S, Thapa RJ, et al. 2013.. Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma. . PLOS ONE 8::e61446
    [Google Scholar]
40. 40.

    Terrett JA, Kalaitzidis D, Dequeant M-L, et al. 2023.. Abstract ND02: CTX112 and CTX131: next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors. . Cancer Res. 83:(Suppl. 7):ND02
    [Google Scholar]
41. 41.

    Ji F, Zhang F, Zhang M, et al. 2021.. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. . J. Hematol. Oncol. 14::152
    [Google Scholar]
42. 42.

    Riether C, Pabst T, Hopner S, et al. 2020.. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. . Nat. Med. 26::1459–67
    [Google Scholar]
43. 43.

    Pabst T, Vey N, Ades L, et al. 2023.. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. . Haematologica 108::1793–802
    [Google Scholar]